Selected Publications
Daniel S Lefler, Marni Brisson Tierno, Babar Bashir.: Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. Cancer Biol Ther 23 (1): 112-116,2022.
Daniel S Lefler, Adam E Snook, Babar Bashir.: Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1. Immunotherapy
14 (11): 885-902,2022.
Amy L Shaver, Swapnil Sharma, Nikita Nikita, Daniel S Lefler, Atrayee Basu-Mallick, Jennifer M Johnson, Meghan Butryn, Grace Lu-Yao.: The Effects of Physical Activity on Cancer Patients Undergoing Treatment with Immune Checkpoint Inhibitors: A Scoping Review Cancers (Basel)
13 (24): 6364,2021.
Allyson M Pishko, Robert K Andrews, Elizabeth E Gardiner, Daniel S Lefler, Adam Cuker.: Soluble glycoprotein VI is a predictor of major bleeding in patients with suspected heparin-induced thrombocytopenia. Blood Adv 4 (18): 4327-4332.,2020.
Daniel S Lefler, Adam Cuker, Lori-Ann Linkins, Theodore E Warkentin, Allyson M Pishko.: Maximum 24-hour platelet count fall: Metric for improving the diagnosis of heparin-induced thrombocytopenia among patients with intermediate probability 4Ts scores J Thromb Haemost 18 (8): 2018-2024,2020.
Allyson M Pishko, Daniel S Lefler, Phyllis Gimotty, Koosha Paydary, Sara Fardin, Gowthami M Arepally, Mark Crowther, Lawrence Rice, Rolando Vega, Douglas B Cines, James P Guevara, Adam Cuker.: The risk of major bleeding in patients with suspected heparin‐induced thrombocytopenia. J Thromb Haemost
17 (11): 1956-1965,2019.
Academic Contact Information
Perelman Center for Advanced Medicine
3400 Civic Center Blvd
10-145 South Pavilion
Philadelphia,
PA
19104
Patient appointments: 800-789-7366